These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37357381)

  • 1. The proteinuria-lowering effects of dapagliflozin are associated with an initial decline in estimated glomerular filtration rate in patients with chronic kidney disease.
    Murakoshi M; Kobayashi T; Kihara M; Ueda S; Suzuki Y; Gohda T
    Nephrology (Carlton); 2023 Oct; 28(10):540-547. PubMed ID: 37357381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.
    Wheeler DC; Jongs N; Stefansson BV; Chertow GM; Greene T; Hou FF; Langkilde AM; McMurray JJV; Rossing P; Nowicki M; Wittmann I; Correa-Rotter R; Sjöström CD; Toto RD; Heerspink HJL;
    Nephrol Dial Transplant; 2022 Aug; 37(9):1647-1656. PubMed ID: 34850160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus.
    Shibata R; Taguchi K; Kaida Y; Fukami K
    Clin Exp Nephrol; 2023 Jan; 27(1):44-53. PubMed ID: 36114995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
    Cherney DZI; Dekkers CCJ; Barbour SJ; Cattran D; Abdul Gafor AH; Greasley PJ; Laverman GD; Lim SK; Di Tanna GL; Reich HN; Vervloet MG; Wong MG; Gansevoort RT; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2020 Jul; 8(7):582-593. PubMed ID: 32559474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD.
    Jongs N; Chertow GM; Greene T; McMurray JJV; Langkilde AM; Correa-Rotter R; Kashihara N; Rossing P; Sjöström CD; Stefánsson BV; Toto RD; Wheeler DC; Heerspink HJL; ;
    J Am Soc Nephrol; 2022 Nov; 33(11):2094-2107. PubMed ID: 35977807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials.
    Idzerda NMA; Pena MJ; Parving HH; de Zeeuw D; Heerspink HJL
    Nephrol Dial Transplant; 2019 Oct; 34(10):1699-1706. PubMed ID: 30184238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The dapagliflozin and prevention of adverse outcomes in chronic kidney disease: results of the DAPA-CKD study].
    Batyushin MM
    Ter Arkh; 2021 Jun; 93(6):713-723. PubMed ID: 36286839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
    Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
    Heerspink HJL; Cherney D; Postmus D; Stefánsson BV; Chertow GM; Dwyer JP; Greene T; Kosiborod M; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Toto RD; Wheeler DC;
    Kidney Int; 2022 Jan; 101(1):174-184. PubMed ID: 34560136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
    Dekkers CCJ; Wheeler DC; Sjöström CD; Stefansson BV; Cain V; Heerspink HJL
    Nephrol Dial Transplant; 2018 Nov; 33(11):2005-2011. PubMed ID: 29370424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
    Chertow GM; Vart P; Jongs N; Toto RD; Gorriz JL; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefánsson BV; Langkilde AM; Wheeler DC; Heerspink HJL;
    J Am Soc Nephrol; 2021 Sep; 32(9):2352-2361. PubMed ID: 34272327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the utility of the urine dipstick and urine protein-to-creatinine ratio for predicting microalbuminuria in patients with non-diabetic lifestyle-related diseases -a comparison with diabetes.
    Ogi M; Seto T; Wakabayashi Y
    BMC Nephrol; 2022 Nov; 23(1):377. PubMed ID: 36434544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
    Waijer SW; Vart P; Cherney DZI; Chertow GM; Jongs N; Langkilde AM; Mann JFE; Mosenzon O; McMurray JJV; Rossing P; Correa-Rotter R; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL
    Diabetologia; 2022 Jul; 65(7):1085-1097. PubMed ID: 35445820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
    Wheeler DC; Toto RD; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Pecoits-Filho R; Correa-Rotter R; Rossing P; Sjöström CD; Umanath K; Langkilde AM; Heerspink HJL;
    Kidney Int; 2021 Jul; 100(1):215-224. PubMed ID: 33878338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating Time to ESRD in Children With CKD.
    Furth SL; Pierce C; Hui WF; White CA; Wong CS; Schaefer F; Wühl E; Abraham AG; Warady BA; ;
    Am J Kidney Dis; 2018 Jun; 71(6):783-792. PubMed ID: 29653769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive Decline in Estimated GFR in Patients With Sickle Cell Disease: An Observational Cohort Study.
    Derebail VK; Ciccone EJ; Zhou Q; Kilgore RR; Cai J; Ataga KI
    Am J Kidney Dis; 2019 Jul; 74(1):47-55. PubMed ID: 30797615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.